Insmed | INSM - Current Liabilities


Insmed reported $311.68M in Current Liabilities for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 2.48B
Cash and Equivalent USD 1.28B
Cost of Sales USD 29.34M
Current Assets USD 2.08B
Current Liabilities USD 311.68M
Debt USD 564.1M
EBIT USD -253.88M
EBITDA USD -297.13M
Employees 1.27K
EPS Earnings Per Share USD -1.7
Equity Capital and Reserves USD 1.25B
Gross Profit on Sales USD 78.08M
Interest Expense on Debt USD 21.25M
Interest Income USD 0
Loan Capital USD 560.95M
Market Capitalization USD 21.64B
Net Income USD -321.69M
Operating Expenses USD 361.29M
Operating Profit USD -253.88M
Ordinary Share Capital USD 211.11M
Pre-Tax Profit USD -320.44M
Sales Revenues USD 107.4M
Selling and Administration Expenses USD 76.44M
Stock USD 107.61M
Trade Creditors USD 78.35M
Trade Debtors USD 55.03M

Current Liabilities Change Date
BioMarin Pharmaceutical USD 684.25M 56.03M Jun/2025
Cytokinetics USD 131.06M 28.66M Jun/2025
DBV Technologies USD 49.42M 9.04M Jun/2025
Dynavax Technologies USD 118.23M 49.85M Jun/2025
Gilead Sciences USD 11.19B 1.15B Jun/2025
Insmed USD 311.68M 72.45M Jun/2025
Novartis USD 31.71B 3.02B Jun/2025
Regeneron Pharmaceuticals USD 3.67B 100.4M Jun/2025
Sarepta Therapeutics USD 919.95M 314.36M Jun/2025
Ultragenyx Pharmaceutical USD 293.24M 1.58M Jun/2025
Vertex Pharmaceuticals USD 4.14B 355.2M Jun/2025